Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor More than 4 years after the first description of exenatide-related pancreatitis, the recent study by Singh et al1 reports a 2-fold increased risk of hospital admission for acute pancreatitis with glucagon-like peptide 1 (GLP-1) mimetics, compared with other antidiabetics.1 The study has immediately fuelled the debate on this topic,2 but a different design is definitely needed to fully elucidate this issue in a more comprehensive clinical perspective.
Raschi E, Piccinni C, Marchesini G. Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety. JAMA Intern Med. 2013;173(19):1843. doi:10.1001/jamainternmed.2013.8150